The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
Current Strategies to Target Tumor-Associated-Macrophages to Improve Anti-Tumor Immune Responses
Open accessAbstract
: Established evidence demonstrates that tumor-infiltrating myeloid cells promote rather than stop-cancer progression. Tumor-associated macrophages (TAMs) are abundantly present at tumor sites, and here they support cancer proliferation and distant spreading, as well as contribute to an immune-suppressive milieu. Their pro-tumor activities hamper the response of cancer patients to conventional therapies, such as chemotherapy or radiotherapy, and also to immunotherapies based on checkpoint inhibition. Active research frontlines of the last years have investigated novel therapeutic strategies aimed at depleting TAMs and/or at reprogramming their tumor-promoting effects, with the goal of re-establishing a favorable immunological anti-tumor response within the tumor tissue. In recent years, numerous clinical trials have included pharmacological strategies to target TAMs alone or in combination with other therapies. This review summarizes the past and current knowledge available on experimental tumor models and human clinical studies targeting TAMs for cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
Self-citationChen, W., Jin, W., Hardegen, N., Lei, K.-J., Li, L., Marinos, N., McGrady, G., & Wahl, S. M. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030152 · Cited by 4,699
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,033
Self-citationImmunogenic Cell Death in Cancer Therapy
Kroemer, G., Galluzzi, L., Kepp, O., & Zitvogel, L. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-100008 · Cited by 3,303
The Tumor Microenvironment Innately Modulates Cancer Progression
Hinshaw, D. C., & Shevde, L. A. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3962 · Cited by 3,270
Fate Mapping Reveals Origins and Dynamics of Monocytes and Tissue Macrophages under Homeostasis
Yona, S., Kim, K.-W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, S., Guilliams, M., Misharin, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.12.001 · Cited by 3,245
Functional Polarization of Tumour-Associated Macrophages by Tumour-Derived Lactic Acid
Colegio, O. R., Chu, N.-Q., Szabo, A. L., Chu, T., Rhebergen, A. M., Jairam, V., Cyrus, N., Brokowski, C. E., Eisenbarth, S. C., Phillips, G. M., et al. (2014) · Nature · doi:10.1038/nature13490 · Cited by 3,046
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., et al. (2017) · Nature · doi:10.1038/nature22396 · Cited by 2,247
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Macrophages and metabolism in the tumor microenvironment
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G., & Galluzzi, L. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.06.001 · Cited by 1,837 · cited 1×
“circulating monocytes) is not a mere classification connected to their localization but seems to influence their activity and phenotypic profile [12,13].”
BackgroundDeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715
CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans
Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., et al. (2011) · Science · doi:10.1126/science.1198443 · Cited by 1,672
Zanganeh, S., Hutter, G., Spitler, R., Lenkov, O., Mahmoudi, M., Shaw, A., Pajarinen, J. S., Nejadnik, H., Goodman, S., Moseley, M., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.168 · Cited by 1,647
Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy
Lin, E. Y., Nguyen, A. V., Russell, R. G., & Pollard, J. W. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.6.727 · Cited by 1,594
Tumour-intrinsic resistance to immune checkpoint blockade
Kalbasi, A., & Ribas, A. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0218-4 · Cited by 1,486
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Ries, C. H., Cannarile, M. A., Hoves, S., Benz, J., Wartha, K., Runza, V., Rey-Giraud, F., Pradel, L. P., Feuerhake, F., Klaman, I., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.016 · Cited by 1,384
TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance
Thomas, D. A., & Massagué, J. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.10.012 · Cited by 1,355
Zhu, Y., Knolhoff, B. L., Meyer, M. A., Nywening, T. M., West, B. L., Luo, J., Wang-Gillam, A., Goedegebuure, S. P., Linehan, D. C., & DeNardo, D. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3723 · Cited by 1,324
PI3Kγ is a molecular switch that controls immune suppression
Kaneda, M. M., Messer, K. S., Ralainirina, N., Li, H., Leem, C. J., Gorjestani, S., Woo, G., Nguyen, A. V., Figueiredo, C. C., Foubert, P., et al. (2016) · Nature · doi:10.1038/nature19834 · Cited by 1,173
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma
Advani, R., Flinn, I., Popplewell, L., Forero, A., Bartlett, N. L., Ghosh, N., Kline, J., Roschewski, M., LaCasce, A., Collins, G. P., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1807315 · Cited by 1,126
Klug, F., Prakash, H., Huber, P. E., Seibel, T., Bender, N., Halama, N., Pfirschke, C., Voss, R. H., Timke, C., Umansky, L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.09.014 · Cited by 1,099
Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099
Macrophage Regulation of Tumor Responses to Anticancer Therapies
De Palma, M., & Lewis, C. E. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.02.013 · Cited by 1,079
Ruffell, B., Chang-Strachan, D., Chan, V., Rosenbusch, A., Ho, C. M. T., Pryer, N., Daniel, D., Hwang, E. S., Rugo, H. S., & Coussens, L. M. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.006 · Cited by 1,008
Peranzoni, E., Lemoine, J., Vimeux, L., Feuillet, V., Barrin, S., Kantari-Mimoun, C., Bercovici, N., Guérin, M., Biton, J., Ouakrim, H., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720948115 · Cited by 919
Kuang, D.-M., Zhao, Q., Peng, C., Xu, J., Zhang, J.-P., Wu, C., & Zheng, L. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082173 · Cited by 903
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Self-citationOvercoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
De Henau, O., Rausch, M., Winkler, D., Campesato, L. F., Liu, C., Cymerman, D. H., Budhu, S., Ghosh, A., Pink, M., Tchaicha, J., et al. (2016) · Nature · doi:10.1038/nature20554 · Cited by 860
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Chen, B. J., Chapuy, B., Ouyang, J., Sun, H. H., Roemer, M. G. M., Xu, M. L., Yu, H., Fletcher, C. D. M., Freeman, G. J., Shipp, M. A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0855 · Cited by 843
Goswami, S., Sahai, E., Wyckoff, J. B., Cammer, M., Cox, D., Pixley, F. J., Stanley, E. R., Segall, J. E., & Condeelis, J. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-1853 · Cited by 738
Metabolic Reprogramming of Immune Cells in Cancer Progression
Biswas, S. K. (2015) · Immunity · doi:10.1016/j.immuni.2015.09.001 · Cited by 721
Origins of tumor-associated macrophages and neutrophils
Cortez-Retamozo, V., Etzrodt, M., Newton, A., Rauch, P. J., Chudnovskiy, A., Berger, C., Ryan, R. J. H., Iwamoto, Y., Marinelli, B., Gorbatov, R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113744109 · Cited by 689
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M.-M., Wyckoff, J., Mertz, K. D., Varga, Z., Junt, T., & Bentires-Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 665
Kumar, V., Donthireddy, L., Marvel, D., Condamine, T., Wang, F., Lavilla-Alonso, S., Hashimoto, A., Vonteddu, P., Behera, R., Goins, M. A., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.005 · Cited by 653
Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., & Tedder, T. F. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040119 · Cited by 642
Mazzieri, R., Pucci, F., Moi, D., Zonari, E., Ranghetti, A., Berti, A., Politi, L. S., Gentner, B., Brown, J. L., Naldini, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.02.005 · Cited by 639
PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells
Loke, P., & Allison, J. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0931259100 · Cited by 634
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 616
Self-citationGao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Xu, J., Escamilla, J., Mok, S., David, J., Priceman, S., West, B., Bollag, G., McBride, W., & Wu, L. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3981 · Cited by 569
Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages
Guerriero, J. L., Sotayo, A., Ponichtera, H. E., Castrillon, J. A., Pourzia, A. L., Schad, S., Johnson, S. F., Carrasco, R. D., Lazo, S., Bronson, R. T., et al. (2017) · Nature · doi:10.1038/nature21409 · Cited by 558
Zhu, X.-D., Zhang, J.-B., Zhuang, P.-Y., Zhu, H.-G., Zhang, W., Xiong, Y.-Q., Wu, W.-Z., Wang, L., Tang, Z.-Y., & Sun, H.-C. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.6521 · Cited by 556
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers
Zhang, F., Parayath, N. N., Ene, C. I., Stephan, S. B., Koehne, A. L., Coon, M. E., Holland, E. C., & Stephan, M. T. (2019) · Nature Communications · doi:10.1038/s41467-019-11911-5 · Cited by 521
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Hughes, R., Qian, B.-Z., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O. C., Tazzyman, S., Danson, S., Addison, C., Clemons, M., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3587 · Cited by 518
Macrophage Metabolism Controls Tumor Blood Vessel Morphogenesis and Metastasis
Wenes, M., Shang, M., Di Matteo, M., Goveia, J., Martín-Pérez, R., Serneels, J., Prenen, H., Ghesquière, B., Carmeliet, P., & Mazzone, M. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.09.008 · Cited by 496
Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer
Gunderson, A. J., Kaneda, M. M., Tsujikawa, T., Nguyen, A. V., Affara, N. I., Ruffell, B., Gorjestani, S., Liudahl, S. M., Truitt, M., Olson, P., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0827 · Cited by 486
Nakasone, E. S., Askautrud, H. A., Kees, T., Park, J.-H., Plaks, V., Ewald, A. J., Fein, M., Rasch, M. G., Tan, Y.-X., Qiu, J., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.017 · Cited by 478
Winograd, R., Byrne, K. T., Evans, R. A., Odorizzi, P. M., Meyer, A. R. L., Bajor, D. L., Clendenin, C., Stanger, B. Z., Furth, E. E., Wherry, E. J., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0215 · Cited by 459
Bloch, O., Crane, C. A., Kaur, R., Safaee, M., Rutkowski, M. J., & Parsa, A. T. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3314 · Cited by 458
Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages
Bohn, T., Rapp, S., Luther, N., Klein, M., Bruehl, T.-J., Kojima, N., Aranda Lopez, P., Hahlbrock, J., Muth, S., Endo, S., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0226-8 · Cited by 436
The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
Foekens, J. A., Peters, H. A., Look, M. P., Portengen, H., Schmitt, M., Kramer, M. D., Brünner, N., Jänicke, F., Gelder, M. E. M., Henzen-Logmans, S. C., et al. (2000) · PubMed · Cited by 419
Laoui, D., Van Overmeire, E., Di Conza, G., Aldeni, C., Keirsse, J., Morias, Y., Movahedi, K., Houbracken, I., Schouppe, E., Elkrim, Y., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1196 · Cited by 412
Allavena, P., & Mantovani, A. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04515.x · Cited by 384
Self-citationSchmid, M. C., Avraamides, C. J., Dippold, H. C., Franco, I., Foubert, P., Ellies, L. G., Acevedo, L. M., Manglicmot, J. R. E., Song, X., Wrasidlo, W., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.016 · Cited by 378
Strachan, D. C., Ruffell, B., Oei, Y., Bissell, M. J., Coussens, L. M., Pryer, N., & Daniel, D. (2013) · OncoImmunology · doi:10.4161/onci.26968 · Cited by 376
Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group
Lobera, M., Madauss, K. P., Pohlhaus, D. T., Wright, Q. G., Trocha, M., Schmidt, D. R., Baloglu, E., Trump, R. P., Head, M. S., Hofmann, G. A., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1223 · Cited by 376
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Regulation of the Macrophage Content of Neoplasms by Chemoattractants
Bottazzi, B., Polentarutti, N., Acero, R., Balsari, A., Boraschi, D., Ghezzi, P., Salmona, M., & Mantovani, A. (1983) · Science · doi:10.1126/science.6828888 · Cited by 352
The chemokine CXCL12 regulates monocyte-macrophage differentiation and RUNX3 expression
Sánchez-Martín, L., Estecha, A., Samaniego, R., Sánchez-Ramón, S., Vega, M. Á., & Sánchez-Mateos, P. (2011) · Blood · doi:10.1182/blood-2009-12-258186 · Cited by 325
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Kalbasi, A., Komar, C., Tooker, G. M., Liu, M., Lee, J. W., Gladney, W. L., Ben-Josef, E., & Beatty, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0870 · Cited by 305
McKinlay, C. J., Vargas, J. R., Blake, T. R., Hardy, J. W., Kanada, M., Contag, C. H., Wender, P. A., & Waymouth, R. M. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614193114 · Cited by 288
Intratumoral macrophages contribute to epithelial-mesenchymal transition in solid tumors
Bonde, A.-K., Tischler, V., Kumar, S., Soltermann, A., & Schwendener, R. A. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-35 · Cited by 283
Di Caro, G., Cortese, N., Castino, G. F., Grizzi, F., Gavazzi, F., Ridolfi, C., Capretti, G., Mineri, R., Todoric, J., Zerbi, A., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-309193 · Cited by 275
Self-citationPascual-García, M., Bonfill-Teixidor, E., Planas-Rigol, E., Rubio-Perez, C., Iurlaro, R., Arias, A., Cuartas, I., Sala-Hojman, A., Escudero, L., Martínez-Ricarte, F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10369-9 · Cited by 262
Colotta, F., Peri, G., Villa, A., & Mantovani, A. (1984) · The Journal of Immunology · doi:10.4049/jimmunol.132.2.936 · Cited by 261
Re-polarization of tumor-associated macrophages to pro-inflammatory M1 macrophages by microRNA-155
Cai, X., Yin, Y., Li, N., Zhu, D., Zhang, J., Zhang, C.-Y., & Zen, K. (2012) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjs044 · Cited by 260
Yan, D., Kowal, J., Akkari, L., Schuhmacher, A. J., Huse, J. T., West, B. L., & Joyce, J. A. (2017) · Oncogene · doi:10.1038/onc.2017.261 · Cited by 236
Zhu, S., Niu, M., O’Mary, H., & Cui, Z. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400216r · Cited by 232
Etzerodt, A., Tsalkitzi, K., Maniecki, M., Damsky, W., Delfini, M., Baudoin, E., Moulin, M., Bosenberg, M., Graversen, J. H., Auphan-Anezin, N., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20182124 · Cited by 229
Candido, J. B., Morton, J. P., Bailey, P., Campbell, A. D., Karim, S. A., Jamieson, T., Lapienyte, L., Gopinathan, A., Clark, W., McGhee, E. J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.131 · Cited by 224
Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors
Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue, N., & Seya, T. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113099109 · Cited by 224
Stafford, J. H., Hirai, T., Deng, L., Chernikova, S. B., Urata, K., West, B. L., & Brown, J. M. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov272 · Cited by 221
Brana, I., Calles, A., LoRusso, P. M., Yee, L. K., Puchalski, T. A., Seetharam, S., Zhong, B., de Boer, C. J., Tabernero, J., & Calvo, E. (2015) · Targeted Oncology · doi:10.1007/s11523-014-0320-2 · Cited by 216
Gomez-Roca, C. A., Italiano, A., Le Tourneau, C., Cassier, P. A., Toulmonde, M., D’Angelo, S. P., Campone, M., Weber, K. L., Loirat, D., Cannarile, M. A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz163 · Cited by 213
The Two Faces of Tumor-Associated Macrophages and Their Clinical Significance in Colorectal Cancer
Pinto, M. L., Rios, E., Durães, C., Ribeiro, R., Machado, J. C., Mantovani, A., Barbosa, M. A., Carneiro, F., & Oliveira, M. J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01875 · Cited by 213
Teresa Pinto, A., Laranjeiro Pinto, M., Patrícia Cardoso, A., Monteiro, C., Teixeira Pinto, M., Filipe Maia, A., Castro, P., Figueira, R., Monteiro, A., Marques, M., et al. (2016) · Scientific Reports · doi:10.1038/srep18765 · Cited by 209
Linde, N., Lederle, W., Depner, S., van Rooijen, N., Gutschalk, C. M., & Mueller, M. M. (2012) · The Journal of Pathology · doi:10.1002/path.3989 · Cited by 195
Kulkarni, A., Chandrasekar, V., Natarajan, S. K., Ramesh, A., Pandey, P., Nirgud, J., Bhatnagar, H., Ashok, D., Ajay, A. K., & Sengupta, S. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0254-6 · Cited by 194
Argyle, D., & Kitamura, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02629 · Cited by 190
Song, Y., Tang, C., & Yin, C. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.017 · Cited by 188
Ramesh, A., Kumar, S., Nandi, D., & Kulkarni, A. (2019) · Advanced Materials · doi:10.1002/adma.201904364 · Cited by 187
Mullins, S. R., Vasilakos, J. P., Deschler, K., Grigsby, I., Gillis, P., John, J., Elder, M. J., Swales, J., Timosenko, E., Cooper, Z., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0724-8 · Cited by 186
Meng, Y., Beckett, M. A., Liang, H., Mauceri, H. J., van Rooijen, N., Cohen, K. S., & Weichselbaum, R. R. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2995 · Cited by 181
Anti-tumor Activity of Toll-Like Receptor 7 Agonists
Chi, H., Li, C., Zhao, F. S., Zhang, L., Ng, T. B., Jin, G., & Sha, O. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00304 · Cited by 180
Ontogeny of Tumor-Associated Macrophages and Its Implication in Cancer Regulation
Franklin, R. A., & Li, M. O. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2015.11.004 · Cited by 175
Tissue-resident versus monocyte-derived macrophages in the tumor microenvironment
Lahmar, Q., Keirsse, J., Laoui, D., Movahedi, K., Overmeire, E. V., & Ginderachter, J. A. V. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.06.009 · Cited by 173
The CD47-SIRP signalling system: its physiological roles and therapeutic application
Murata, Y., Kotani, T., Ohnishi, H., & Matozaki, T. (2014) · Journal of Biochemistry · doi:10.1093/jb/mvu017 · Cited by 169
Quaranta, V., Rainer, C., Nielsen, S. R., Raymant, M. L., Ahmed, M. S., Engle, D. D., Taylor, A., Murray, T., Campbell, F., Palmer, D. H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3876 · Cited by 168
Salvagno, C., Ciampricotti, M., Tuit, S., Hau, C.-S., van Weverwijk, A., Coffelt, S. B., Kersten, K., Vrijland, K., Kos, K., Ulas, T., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0298-1 · Cited by 168
Vidyarthi, A., Khan, N., Agnihotri, T., Negi, S., Das, D. K., Aqdas, M., Chatterjee, D., Colegio, O. R., Tewari, M. K., & Agrewala, J. N. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01650 · Cited by 166
Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity
Perry, C. J., Muñoz-Rojas, A. R., Meeth, K. M., Kellman, L. N., Amezquita, R. A., Thakral, D., Du, V. Y., Wang, J. X., Damsky, W., Kuhlmann, A. L., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20171435 · Cited by 165
Huang, L., Xu, H., & Peng, G. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2018.4 · Cited by 164
Liu, Z., Xie, Y., Xiong, Y., Liu, S., Qiu, C., Zhu, Z., Mao, H., Yu, M., & Wang, X. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.020 · Cited by 164
Wesolowski, R., Sharma, N., Reebel, L., Rodal, M. B., Alexandra, P., West, B. L., Marimuthu, A., Severson, P. L., Karlin, D. A., Dowlati, A., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919854238 · Cited by 163
Wiehagen, K. R., Girgis, N. M., Yamada, D. H., Smith, A. A., Chan, S. R., Grewal, I. S., Quigley, M., & Verona, R. I. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0258 · Cited by 162
Phuengkham, H., Song, C., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201903242 · Cited by 136
Rashidian, M., LaFleur, M. W., Verschoor, V. L., Dongre, A., Zhang, Y., Nguyen, T. H., Kolifrath, S. C., Aref, A. R., Lau, C. J., Paweletz, C. P., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1905005116 · Cited by 132
Local Delivery of Ox40l , Cd80 , and Cd86 mRNA Kindles Global Anticancer Immunity
Haabeth, O. A. W., Blake, T. R., McKinlay, C. J., Tveita, A. A., Sallets, A., Waymouth, R. M., Wender, P. A., & Levy, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2867 · Cited by 129
zhao, J., Zhang, Z., Xue, Y., Wang, G., Cheng, Y. G., Pan, Y., Zhao, S., & Hou, Y. (2018) · Theranostics · doi:10.7150/thno.29746 · Cited by 127
Kuklinski, L. F., Yan, S., Li, Z., Fisher, J. L., Cheng, C., Noelle, R. J., Angeles, C. V., Turk, M. J., & Ernstoff, M. S. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2169-1 · Cited by 123
Leblond, M. M., Pérès, E. A., Hélaine, C., Gérault, A. N., Moulin, D., Anfray, C., Divoux, D., Petit, E., Bernaudin, M., & Valable, S. (2017) · Oncotarget · doi:10.18632/oncotarget.19994 · Cited by 122
Self-citationPiaggio, F., Kondylis, V., Pastorino, F., Paolo, D. D., Perri, P., Cossu, I., Schorn, F., Marinaccio, C., Murgia, D., Daga, A., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.037 · Cited by 121
Patwardhan, P. P., Surriga, O., Beckman, M. J., de Stanchina, E., DeMatteo, R. P., Tap, W. D., & Schwartz, G. K. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2576 · Cited by 119
Reduced microglial CX3CR1 expression delays neurofibromatosis‐1 glioma formation
Pong, W. W., Higer, S. B., Gianino, S. M., Emnett, R. J., & Gutmann, D. H. (2012) · Annals of Neurology · doi:10.1002/ana.23813 · Cited by 116
Contribution of CXCL12 secretion to invasion of breast cancer cells
Boimel, P. J., Смирнова, Т. А., Zhou, Z. N., Wyckoff, J. B., Park, H., Coniglio, S. J., Qian, B., Stanley, E. R., Cox, D., Pollard, J. W., et al. (2012) · Breast Cancer Research · doi:10.1186/bcr3108 · Cited by 113
Engineering macrophages to phagocytose cancer cells by blocking the CD47/SIRPɑ axis
Yang, H., Shao, R., Huang, H., Wang, X., Rong, Z., & Lin, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2332 · Cited by 112
CD163 Is Required for Protumoral Activation of Macrophages in Human and Murine Sarcoma
Shiraishi, D., Fujiwara, Y., Horlad, H., Saito, Y., Iriki, T., Tsuboki, J., Pan, C., Nakagata, N., Mizuta, H., Bekki, H., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2011 · Cited by 109
Bocanegra, A., Ruiz‐de‐Angulo, A., Zabaleta, A., Blanco, N. G., Macarena, B., García-Granda, M. J., Padró, D., Llop, J., Arnáiz, B., Gato, M., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.003 · Cited by 108
The Mononuclear Phagocytic System. Generation of Diversity
Gordon, S., & Plüddemann, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01893 · Cited by 108
The Endless Saga of Monocyte Diversity
Canè, S., Ugel, S., Trovato, R., Marigo, I., Sanctis, F. D., Sartoris, S., & Bronte, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01786 · Cited by 107
Tumor-associated macrophages: a short compendium
Prenen, H., & Mazzone, M. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2997-3 · Cited by 105
Zhang, X., Chen, Y., Hao, L., Hou, A., Chen, X., Li, Y., Wang, R., Luo, P., Ruan, Z., Ou, J., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.08.004 · Cited by 99
Macrophage-Mediated Subversion of Anti-Tumour Immunity
Quaranta, V., & Schmid, M. C. (2019) · Cells · doi:10.3390/cells8070747 · Cited by 98
Macrophages facilitate resistance to anti-VEGF therapy by altered VEGFR expression
Dalton, H. J., Pradeep, S., McGuire, M., Hailemichael, Y., MA, S., Lyons, Y., Armaiz-Pena, G. N., Previs, R. A., Hansen, J. M., Rupaimoole, R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0647 · Cited by 97
Silva, C. G. D., Camps, M. G. M., Li, T. M. W. Y., Chan, A. B., OSSENDORP, F. A., & Cruz, L. J. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119417 · Cited by 89
Targeted Delivery of Zoledronate to Tumor-Associated Macrophages for Cancer Immunotherapy
Zang, X., Zhang, X., Hu, H., Qiao, M., Zhao, X., Deng, Y., & Chen, D. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00261 · Cited by 86
Achyut, B. R., Shankar, A., Iskander, A., Ara, R., Angara, K., Zeng, P., Knight, R. A., Scicli, A. G., & Arbab, A. S. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.09.004 · Cited by 85
Gu, S., Ni, T., Wang, J., Liu, Y., Fan, Q., Wang, Y., Huang, T., Chu, Y., Sun, X., & Wang, Y. (2018) · Journal of Immunology Research · doi:10.1155/2018/6156757 · Cited by 85
Liu, L., He, H., Liang, R., Yi, H., Meng, X., Chen, Z., Pan, H., Ma, Y., & Cai, L. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00239 · Cited by 83
Locatelli, S. L., Careddu, G., Serio, S., Consonni, F. M., Maeda, A., Viswanadha, S., Vakkalanka, S. V. S., Castagna, L., Santoro, A., Allavena, P., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1133 · Cited by 82
Self-citationUnderstanding the Origin and Diversity of Macrophages to Tailor Their Targeting in Solid Cancers
Kielbassa-Elkadi, K., Vegna, S., Ramirez, C. F. A., & Akkari, L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02215 · Cited by 82
Ludwig, H., Weisel, K. C., Petrucci, M. T., Leleu, X. P., Cafro, A. M., Garderet, L., Leitgeb, C., Foà, R., Greil, R., Yakoub‐Agha, I., et al. (2017) · Leukemia · doi:10.1038/leu.2017.5 · Cited by 80
Noman, M. Z., Moer, K. V., Marani, V., Gemmill, R. M., Tranchevent, L.-C., Azuaje, F. J., Muller, A., Chouaïb, S., Thiery, J. P., Berchem, G., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1345415 · Cited by 80
Zhang, J. Q., Zeng, S., Vitiello, G. A., Seifert, A. M., Medina, B. D., Beckman, M. J., Loo, J. K., Santamaria‐Barria, J. A., Maltbaek, J. H., Param, N. J., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0345 · Cited by 71
Borgoni, S., Iannello, A., Cutrupi, S., Allavena, P., D’Incalci, M., Novelli, F., & Cappello, P. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393596 · Cited by 70
Self-citationHypoxia: a double-edged sword of immunity
Sica, A., Melillo, G., & Varesio, L. (2011) · Journal of Molecular Medicine · doi:10.1007/s00109-011-0724-8 · Cited by 66
Maeda, A., Digifico, E., Andon, F. T., Mantovani, A., & Allavena, P. (2019) · European Journal of Immunology · doi:10.1002/eji.201847888 · Cited by 64
Self-citationHasham, M. G., Baxan, N., Stuckey, D. J., Branca, J. A., Perkins, B., Dent, O., Duffy, T., Hameed, T. S., Stella, S. E., Bellahcene, M., et al. (2017) · Disease Models & Mechanisms · doi:10.1242/dmm.027409 · Cited by 60
Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition
Mok, S., Tsoi, J., Koya, R. C., Hu‐Lieskovan, S., West, B. L., Bollag, G. E., Graeber, T. G., & Ribas, A. (2015) · BMC Cancer · doi:10.1186/s12885-015-1377-8 · Cited by 55
Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia
Banerjee, P., Zhang, R., Ivan, C., Galletti, G., Clise-Dwyer, K., Barbaglio, F., Scarfò, L., Aracil, M., Klein, C., Wierda, W. G., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0152 · Cited by 55
The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages
Movahedi, K., & Ginderachter, J. A. V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6704 · Cited by 54
Nadella, V., Singh, S. K., Jain, A., Jain, M., Vásquez, K. M., Sharma, A. K., Tanwar, P., Rath, G. K., & Prakash, H. (2018) · Molecular Carcinogenesis · doi:10.1002/mc.22879 · Cited by 52
Koh, Y. W., Park, C.-S., Yoon, D. H., Suh, C., & Huh, J. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpr92tddfarisu · Cited by 50
Houthuijzen, J. M., Daenen, L. G. M., Roodhart, J. M. L., Oosterom, I., van Jaarsveld, M. T. M., Govaert, K. M., Smith, M. E., Sadatmand, S. J., Rosing, H., Kruse, F., et al. (2014) · Nature Communications · doi:10.1038/ncomms6275 · Cited by 50
Jones, J., Sinder, B. P., Paige, D. J., Soki, F. N., Koh, A. J., Thiele, S., Shiozawa, Y., Hofbauer, L. C., Daignault, S. D., Roca, H., et al. (2018) · Neoplasia · doi:10.1016/j.neo.2018.11.003 · Cited by 50
Thauvin, C., Widmer, J., Mottas, I., Hočevar, S., Allémann, É., Bourquin, C., & Delié, F. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.04.007 · Cited by 42
Kim, Y., Park, S.-J., & Broxmeyer, H. E. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002650 · Cited by 40
Liu, B., Liu, Q., Yang, L., Palaniappan, S. K., Bahar, İ., Thiagarajan, P. S., & Ding, J. L. (2016) · Science Signaling · doi:10.1126/scisignal.aac9340 · Cited by 39
Perkins, H., Khodai, T., Mechiche, H., Colman, P., Burden, F., Laxton, C. D., Horscroft, N., Corey, T., Rodrigues, D., Rawal, J. K., et al. (2012) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9687-y · Cited by 27
Jia, N., Wu, H., Duan, J., Wei, C., Wang, K., Zhang, Y., & Mao, X. (2019) · Journal of Visualized Experiments · doi:10.3791/58660 · Cited by 25
A Robust Nanoparticle Platform for RNA Interference in Macrophages to Suppress Tumor Cell Migration
Liang, S., Zheng, J., Wu, W., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01465 · Cited by 19
Cited by
Harnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment
Wu, K., Lin, K., Li, X., Yuan, X., Xu, P., Ni, P., & Xu, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01731 · Cited by 687
Metabolism of tissue macrophages in homeostasis and pathology
Wculek, S. K., Dunphy, G., Heras-Murillo, I., Mastrangelo, A., & Sancho, D. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00791-9 · Cited by 501
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · Cancer Communications · doi:10.1002/cac2.12539 · Cited by 364
Major pathways involved in macrophage polarization in cancer
Kerneur, C., Cano, C. E., & Olive, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1026954 · Cited by 337
Metadata
- Authors
- Anfray, C., Ummarino, A., Andón, F. T., & Allavena, P.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-12-23
- Volume
- 9
- Issue
- 1
- Pages
- 46
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2996236370
- Cited by
- 304
- References
- 152
- FWCI
- 11.14
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.